Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | FPR1 | P21462 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.45 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323782 | 0.83 | EDNRA (0.48) | KMT2APOLBMEN1ALDH1A1KDM4E | |
| SCHEMBL6316498 | 0.81 | GAA (0.43) | KMT2APOLBMEN1ALDH1A1KDM4E | |
| SCHEMBL6324589 | 0.78 | EDNRA (0.48) | EDNRAEDNRB | |
| SCHEMBL6323274 | 0.77 | KDM4E (0.55) | KMT2APOLBMEN1ALDH1A1KDM4E | |
| SCHEMBL6317676 | 0.76 | EDNRA (0.46) | KMT2AMEN1EDNRAGAAMAPT | |
| SCHEMBL6319053 | 0.76 | HPGDS (0.54) | KMT2APOLBMEN1ALDH1A1KDM4E | |
| SCHEMBL6318626 | 0.75 | SMN1; SMN2 (0.47) | POLBALDH1A1GAAHPGDSMAPT | |
| SCHEMBL6315769 | 0.75 | L3MBTL1 (0.42) | KMT2APOLBMEN1ALDH1A1KDM4E | |
| SCHEMBL6318435 | 0.75 | KDM4E (0.57) | KMT2AMEN1ALDH1A1KDM4ETDP1 | |
| SCHEMBL6316237 | 0.73 | HPGDS (0.47) | POLBKDM4EGAAHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | PFIZER ITALIA S.R.L. (IT) | 2005-03-17 | — | — | US | claimed |
| EP-1435948-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2004-07-14 | — | — | EP | claimed |
| WO-2003013517-A1 | AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | claimed |
| US-20050228018-A1 | Chemical compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059657-A1 | Aminoisoxazole derivatives active as kinase inhibitors | MAP3K9, MAP3K19, MAP4K2 | KMT2A 1089/4885FPR1 3551/4885POLB 872/4885 |
| US-20050228018-A1 | Chemical compounds | CMA1, TPSB2, TPSG1 | KMT2A 2305/4885FPR1 163/4885POLB 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.